COX-2 Gastrointestinal Safety Profile Called Into Question By BMJ Study
This article was originally published in The Tan Sheet
Executive Summary
COX-2 inhibitors do not provide improved safety against gastrointestinal adverse events compared to non-steroidal anti-inflammatory drugs, according to a study published in the Online First edition of the British Medical Journal Dec. 2